AKT kinases as therapeutic targets.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The PI3K/AKT signaling pathway regulates fundamental cellular processes.
• Dysregulation of AKT activity is implicated in various pathologies, including cancer, inflammation, and autoimmune diseases.

Purpose of the Study:

• To review current strategies for targeting the PI3K/AKT pathway.
• To discuss novel approaches, including isoform-specific and mutant-selective inhibitors, for improved therapeutic outcomes.
• To highlight the need for better biomarkers for AKT inhibitor sensitivity.

Main Methods:

• Literature review of PI3K/AKT pathway signaling.
• Analysis of current and emerging AKT inhibitor strategies.
• Discussion of resistance mechanisms and off-target effects.

Main Results:

• Traditional pan-AKT inhibitors face challenges with resistance and toxicity.
• Isoform-centric targeting and mutant-selective covalent allosteric AKT inhibitors (CAAIs) show potential for enhanced efficacy and reduced side effects.
• Development of reliable biomarkers is crucial for predicting patient response.

Conclusions:

• Targeting specific AKT isoforms or mutants may offer a more effective and safer therapeutic strategy than pan-AKT inhibition.
• Novel targeting approaches and improved biomarkers are essential for advancing AKT-targeted therapies.
• Further research into isoform-specific and allele-selective inhibitors holds promise for treating AKT-driven diseases, including cancer and immunotherapy applications.